Name: Current Applications for Overcoming Resistance to Targeted Therapies (en Inglés)
SKU: 57196920
Price: 1691.50 MXN
Availability: InStock
Author: Szewczuk, Myron R. ; Qorri, Bessi ; Sambi, Manpreet
ISBN: 9783030214791

portada Current Applications for Overcoming Resistance to Targeted Therapies (en Inglés)

Current Applications for Overcoming Resistance to Targeted Therapies (en Inglés)

Formato

Libro Físico

Editorial

Springer

Autor

Szewczuk, Myron R. ; Qorri, Bessi ; Sambi, Manpreet

Idioma

Inglés

N° páginas

320

Encuadernación

Tapa Blanda

Dimensiones

23.4x15.6x1.8 cm

Peso

0.48 kg.

ISBN13

9783030214791

Categorías

Anatomía
Oncología
Biología molecular

Current Applications for Overcoming Resistance to Targeted Therapies (en Inglés)

Szewczuk, Myron R. ; Qorri, Bessi ; Sambi, Manpreet (Autor) · Springer · Tapa Blanda

Libro Nuevo Importado

Envío: 13 a 18 días háb.

$ 3,383.00$ 1,691.50

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 1,691.50

¡Envío Gratis! Llega entre el 21 Sep y el 29 Sep a CUAUHTÉMOC, Ciudad de México. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Current Applications for Overcoming Resistance to Targeted Therapies (en Inglés)"

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.